Endpoints Manufacturing: Lonza drops ingredients biz in $4.7B sale; Touchlight's 'doggyboneDNA' looks to rewrite rules of therapeutic DNA
In a CDMO industry flush with cash from Covid-19, the rich keep getting richer — but that doesn’t mean the top dogs aren’t looking for opportunities to offload laggard businesses and rake in some cash. That’s exactly what Lonza did in hiving off its ingredients unit — Endpoints Manufacturing’s top story of the week.
On Monday, the nearly 125-year-old Swiss giant divested its specialty ingredients business in a $4.7 billion deal with Bain Capital and Cinven, the UK private equity firm. The sale will see Bain and Cinven take over Lonza’s 17 ingredients sites around the world, which host some 2,800 workers.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.